Multimodal Treatment Strategies for Gastrointestinal Stromal Tumors

Setting the Stage: Why Multimodal Care Matters for GIST

Gastrointestinal stromal tumors (GISTs) represent less than 1 % of all gastrointestinal neoplasms but are the most common mesenchymal tumors of the tract, with >6 000 new cases annually in the United States. Over half arise in the stomach (≈60 %) and another 30 % in the small intestine; the duodenum, rectum, colon and esophagus are far less frequent. Treatment planning hinges on four prognostic variables: tumor size, mitotic index, anatomic location and the presence of intra‑operative or spontaneous rupture. Larger, high‑mitotic, non‑gastric lesions and ruptured tumors carry a markedly higher recurrence risk, prompting adjuvant tyrosine‑kinase inhibitor therapy. Modern care increasingly relies on a multidisciplinary team—surgical oncology, medical oncology, radiology, pathology, genetics and interventional specialties—to integrate surgical resection, neoadjuvant or adjuvant imatinib, minimally invasive techniques (laparoscopic, robotic, LECS) and emerging modalities such as AI‑driven imaging, thereby personalizing therapy and improving long‑term outcomes, and fostering research initiatives that translate novel evidence into practice.

Surgical Foundations: From Open Resection to Minimally Invasive Techniques

Radical resection with negative margins remains the only potentially curative option for localized gastrointestinal stromal tumors (GISTs). While open surgery was historically the standard, contemporary data demonstrate that laparoscopic wedge resection (LR) provides oncologic safety comparable to open approaches, with the added benefits of reduced blood loss, shorter hospital stay, and faster recovery. Meta‑analyses now support LR for gastric GISTs larger than 5 cm, challenging earlier size restrictions. For tumors located at technically demanding sites such as the esophagogastric junction, posterior wall, or pyloric ring, robotic assistance and laparoscopic intragastric surgery (LIS) expand minimally invasive feasibility while preserving oncologic principles. Laparoscopic Endoscopic Cooperative Surgery (LECS) combines LR and endoscopic techniques to achieve en‑bloc resection; pooled analyses report a 100 % R0 resection rate and a recurrence rate of ~0.2 %, with overall complication rates lower than either LR or endoscopic resection alone, despite longer operative times. These advances underscore a shift toward organ‑preserving, minimally invasive strategies that maintain the curative intent of radical surgery.

Endoscopic Resection Strategies for Small and Medium‑Sized Gastric GISTs

Endoscopic submucosal dissection (ESD), submucosal tunneling endoscopic resection (STER), endoscopic full‑thickness resection (EFTR), and endoscopic muscularis propria‑preserving lesion resection (EMSLD) are indicated for gastric GISTs that are ≤5 cm, confined to the submucosa or muscularis propria, and lack serosal invasion. High‑risk features such as ulceration, irregular borders, or heterogeneity may also prompt resection even for lesions <2 cm. Recent series demonstrate that en‑bloc removal of tumors up to 5 cm can be performed safely endoscopically, achieving R0 margins without the need for open surgery when the serosal layer is intact. Hybrid techniques—including endoscopic inversion and strangulation of the muscle layer (EISMR) and full‑thickness resection devices (FTRD)—combine the precision of endoscopy with controlled transmural resection, reducing the risk of perforation and intra‑operative tumor rupture. Meta‑analyses show that pure endoscopic approaches have slightly higher overall complication rates (e.g., bleeding, perforation) compared with hybrid methods, while hybrid procedures report lower morbidity and comparable oncologic outcomes. Consequently, for selected medium‑size gastric GISTs, hybrid endoscopic‑surgical strategies are increasingly favored to balance safety and curative resection.

Targeted Therapy Integration: Neoadjuvant and Adjuvant Tyrosine‑Kinase Inhibitors

Imatinib is the cornerstone first‑line tyrosine‑kinase inhibitor (TKI) for gastrointestinal stromal tumors. In the neoadjuvant setting it is used to shrink large or borderline‑resectable gastric and small‑intestinal GISTs, increasing the likelihood of an R0 resection and preserving organ function. Molecular profiling of the tumor is mandatory before initiating systemic therapy; KIT exon 11 mutations respond well to standard‑dose imatinib (400 mg daily), KIT exon 9 mutations may benefit from dose escalation to 800 mg daily, and PDGFRA D842V‑mutant tumors are resistant to imatinib and are instead treated with avapritinib. SDH‑deficient, NTRK‑fusion, or other rare molecular subtypes also require tailored agents or trial enrollment. After complete surgical removal of a high‑risk GIST—defined by size >5 cm, high mitotic index, non‑gastric location, or tumor rupture—adjuvant imatinib for at least three years is recommended, providing a substantial improvement in recurrence‑free survival and overall survival compared with shorter courses. When disease progresses on imatinib, second‑line sunitinib (50 mg daily, 4‑weeks‑on/2‑weeks‑off) is the standard, followed by third‑line regorafenib (160 mg daily, 3‑weeks‑on/1‑week‑off. For patients who have exhausted these options, fourth‑line ripretinib, which targets a broad spectrum of secondary KIT/PDGFRA mutations, and avapritinib for PDGFRA‑exon 18 mutations are approved. Continuous multidisciplinary evaluation, including repeat imaging every 3–6 months and reassessment of mutational status, ensures optimal sequencing of TKIs and maximizes long‑term disease control.

Risk Stratification, Surveillance, and Emerging AI‑Assisted Imaging

Accurate risk stratification is the cornerstone of GIST management. The most influential prognostic variables are tumor size, mitotic index (mitoses per 50 high‑power fields), site, and the presence of intra‑operative or spontaneous rupture. Both the modified NIH criteria and NCCN risk categories integrate these factors to assign patients to low, intermediate, or high‑risk groups, which directly dictate adjuvant therapy decisions—high‑risk patients receive at least three years of imatinib, whereas low‑risk disease may be observed. Post‑resection surveillance mirrors this risk‑based approach: contrast‑enhanced CT or MRI of the abdomen and pelvis is performed every 3–6 months for the first 2–3 years in high‑risk patients, with intervals subsequently lengthened; low‑risk patients are imaged less frequently, often every 6–12 months after the initial year. Emerging artificial‑intelligence‑assisted imaging is poised to refine early detection and pre‑operative risk assessment of small gastric GISTs. Deep‑learning models can automatically quantify features such as ulceration, irregular borders, and heterogeneity on CT or MRI, providing a quantitative risk score that correlates with mitotic activity and recurrence probability. This technology promises to augment clinician decision‑making, allowing more precise selection of patients for surveillance versus early resection and potentially improving outcomes through tailored multimodal therapy.

Multidisciplinary Care and Future Directions in GIST Treatment

Optimal management of gastrointestinal stromal tumors (GIST) hinges on a coordinated multidisciplinary team that integrates surgical oncology, medical oncology, radiology, pathology, genetics, and supportive‑care services. Tumor boards review each case to decide the sequence of interventions—whether to proceed with upfront resection, neoadjuvant imatinib to downsize borderline‑resectable disease, or incorporate local ablative modalities such as radiofrequency ablation for oligometastatic liver lesions. This collaborative approach ensures that R0 resection is achieved while avoiding intra‑operative rupture, a known predictor of recurrence, and that adjuvant therapy is prescribed for high‑risk patients.

The clinical‑trial landscape is expanding rapidly. Fourth‑line agents such as ripretinib and PD‑specific inhibitors like avapritinib have demonstrated activity against secondary KIT/PDGFRA mutations, and combination strategies (e.g., imatinib plus immune‑checkpoint blockade) are under investigation to overcome resistance. Prospective studies are also evaluating novel TKIs and hybrid regimens that integrate systemic therapy with minimally invasive surgery (laparoscopic, robotic, or LECS).

Emerging multimodal predictive models that fuse radiomics from pre‑operative CT, pathomics from whole‑slide imaging, and clinical risk factors (size, mitotic index, mutation status) show promise for refined recurrence‑free survival stratification, guiding personalized adjuvant TKI duration and surveillance intensity. Continued validation of these models in prospective trials will further align precision medicine with multidisciplinary GIST care.

Looking Ahead: Personalizing GIST Therapy Through Collaboration and Innovation

Integrating radical resection with adjuvant or neoadjuvant tyrosine‑kinase inhibitors has consistently extended recurrence‑free and overall survival for localized and metastatic GIST. Large series and meta‑analyses show that patients receiving R0 surgery plus at least three years of imatinib experience markedly lower relapse rates than surgery alone. Precise molecular profiling—identifying KIT, PDGFRA, SDH or NTRK alterations—guides selection of imatinib, avapritinib, sunitinib or emerging agents, ensuring risk‑adjusted adjuvant regimens that match tumor biology. Because resistance patterns evolve, enrolling patients in genotype‑driven clinical trials is essential to refine multimodal standards and bring novel therapies to practice. Such collaboration will improve patient outcomes worldwide.